欧康医药
(833230)
| 流通市值：9.87亿 | | | 总市值：21.23亿 |
| 流通股本：3593.00万 | | | 总股本：7726.73万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 18,967,926.25 | 13,734,086.77 | 24,000,446.44 | 51,521,096.61 |
| 应收票据及应收账款 | 79,838,351.47 | 65,615,700.68 | 68,130,075.97 | 63,663,660.23 |
| 其中：应收票据 | - | 83,946 | - | 400,000 |
| 应收账款 | 79,838,351.47 | 65,531,754.68 | 68,130,075.97 | 63,263,660.23 |
| 预付款项 | 24,268,872.52 | 23,777,618.8 | 10,041,006.97 | 3,426,414.9 |
| 其他应收款合计 | 2,897,125.92 | 2,846,062.81 | 3,140,138.88 | 2,904,403.48 |
| 存货 | 74,678,189.19 | 76,601,578.69 | 74,387,598.57 | 73,931,694.95 |
| 其他流动资产 | 3,727,076.41 | 5,964,060.21 | 4,415,165.13 | 5,343,318.82 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 234,863,474.45 | 221,065,379.8 | 252,728,292.63 | 294,402,629.11 |
| 非流动资产: | | | | |
| 固定资产 | 201,165,094.89 | 30,778,084.61 | 31,616,052.2 | 32,984,623 |
| 在建工程 | 43,880,439.69 | 168,654,074 | 140,573,206.76 | 112,683,779.55 |
| 使用权资产 | 160,654.37 | 195,080.51 | 234,467.83 | 263,932.45 |
| 无形资产 | 11,348,231.25 | 11,491,980.08 | 11,636,631.14 | 11,779,781.5 |
| 递延所得税资产 | 1,478,804.06 | 1,245,853.4 | 936,985.1 | 936,985.1 |
| 其他非流动资产 | - | - | - | 41,398.94 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 258,033,224.26 | 212,365,072.6 | 184,997,343.03 | 158,690,500.54 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 492,896,698.71 | 433,430,452.4 | 437,725,635.66 | 453,093,129.65 |
| 流动负债: | | | | |
| 短期借款 | 20,032,336.71 | 20,046,835.33 | 11,014,703.4 | 21,015,726.03 |
| 应付票据及应付账款 | 46,370,419 | 8,132,986.21 | 11,429,255.93 | 30,881,997.83 |
| 应付账款 | 46,370,419 | 8,132,986.21 | 11,429,255.93 | 30,881,997.83 |
| 合同负债 | 1,268,823.26 | 942,929.33 | 1,314,206.48 | 541,740.35 |
| 应付职工薪酬 | 4,009,296.99 | 2,686,778.14 | 2,724,600.05 | 2,394,197.71 |
| 应交税费 | 88,180.08 | 75,496.94 | 1,685,249.44 | 166,200.41 |
| 其他应付款合计 | 6,115,913.02 | 1,789,972.4 | 439,524.12 | 624,036.16 |
| 一年内到期的非流动负债 | - | - | 143,359.08 | 149,888.93 |
| 其他流动负债 | - | 122,580.81 | - | 70,426.25 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 77,884,969.06 | 33,797,579.16 | 28,750,898.5 | 55,844,213.67 |
| 非流动负债: | | | | |
| 递延收益 | 5,229,200.38 | 5,307,595.3 | 5,295,690.22 | 3,874,085.13 |
| 其他非流动负债 | - | - | 166,371.57 | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 5,229,200.38 | 5,307,595.3 | 5,462,061.79 | 3,874,085.13 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 83,114,169.44 | 39,105,174.46 | 34,212,960.29 | 59,718,298.8 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 77,267,304 | 75,631,404 | 75,631,404 | 75,631,404 |
| 资本公积 | 213,510,243.94 | 206,036,776.38 | 205,945,776.39 | 205,854,776.4 |
| 其他综合收益 | 49,822.77 | 75,970.96 | - | -19,067.58 |
| 专项储备 | 3,108,121.77 | 2,363,734.94 | 1,655,083.68 | 904,552.09 |
| 盈余公积 | 16,194,401.47 | 16,194,401.47 | 16,194,401.47 | 16,194,401.47 |
| 未分配利润 | 99,043,157.35 | 93,364,569.18 | 103,298,286.15 | 94,643,346.54 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 409,173,051.3 | 393,666,856.93 | 402,724,951.69 | 393,209,412.92 |
| 少数股东权益 | 609,477.97 | 658,421.01 | 787,723.68 | 165,417.93 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 409,782,529.27 | 394,325,277.94 | 403,512,675.37 | 393,374,830.85 |
| 负债和股东权益合计 | 492,896,698.71 | 433,430,452.4 | 437,725,635.66 | 453,093,129.65 |
| 公告日期 | 2024-10-30 | 2024-08-27 | 2024-04-26 | 2024-04-17 |
| 审计意见(境内) | | | | 标准无保留意见 |